secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084291
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics regains Nasdaq compliance; subject to one-year monitoring period
------------------------------------------------------------------------------

- Nasdaq Hearings Panel found Company regained compliance with all continued listing rules on Feb 26, 2026.
- Company demonstrated compliance with Equity Rule by Dec 31, 2025 and other rules by Feb 16, 2026.
- Company subject to Mandatory Panel Monitor for one year; immediate delisting if Equity Rule violated again.
- If non-compliant during monitor, Staff will issue Delist Determination Letter; Company can request new hearing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526084291/0001193125-26-084291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526084291/hcwb-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer